Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gossamer Bio (GOSS) Common Equity (2022 - 2025)

Historic Common Equity for Gossamer Bio (GOSS) over the last 4 years, with Q3 2025 value amounting to -$82.3 million.

  • Gossamer Bio's Common Equity fell 25208.55% to -$82.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$82.3 million, marking a year-over-year decrease of 25208.55%. This contributed to the annual value of $29.5 million for FY2024, which is 5301.5% down from last year.
  • Latest data reveals that Gossamer Bio reported Common Equity of -$82.3 million as of Q3 2025, which was down 25208.55% from -$46.1 million recorded in Q2 2025.
  • In the past 5 years, Gossamer Bio's Common Equity registered a high of $104.6 million during Q3 2023, and its lowest value of -$82.3 million during Q3 2025.
  • Its 4-year average for Common Equity is $14.4 million, with a median of $26.7 million in 2024.
  • Within the past 5 years, the most significant YoY rise in Gossamer Bio's Common Equity was 41974.0% (2023), while the steepest drop was 28150.78% (2023).
  • Quarter analysis of 4 years shows Gossamer Bio's Common Equity stood at $12.1 million in 2022, then surged by 419.74% to $62.8 million in 2023, then tumbled by 53.02% to $29.5 million in 2024, then plummeted by 379.17% to -$82.3 million in 2025.
  • Its last three reported values are -$82.3 million in Q3 2025, -$46.1 million for Q2 2025, and -$6.2 million during Q1 2025.